- Home
- NAUT vs SPRO Comparison
NAUT vs SPRO Comparison
Compare NAUT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- SPRO
- Stock Information
- Founded
- NAUT 2016
- SPRO 2013
- Country
- NAUT United States
- SPRO United States
- Employees
- NAUT N/A
- SPRO N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- NAUT Industrials
- SPRO Health Care
- Exchange
- NAUT Nasdaq
- SPRO Nasdaq
- Market Cap
- NAUT 104.7M
- SPRO 110.9M
- IPO Year
- NAUT N/A
- SPRO 2017
- Fundamental
- Price
- NAUT $0.90
- SPRO $2.26
- Analyst Decision
- NAUT Strong Sell
- SPRO Buy
- Analyst Count
- NAUT 1
- SPRO 4
- Target Price
- NAUT $1.75
- SPRO $5.00
- AVG Volume (30 Days)
- NAUT 394.7K
- SPRO 308.6K
- Earning Date
- NAUT 10-28-2025
- SPRO 11-13-2025
- Dividend Yield
- NAUT N/A
- SPRO N/A
- EPS Growth
- NAUT N/A
- SPRO N/A
- EPS
- NAUT N/A
- SPRO N/A
- Revenue
- NAUT N/A
- SPRO $48,576,000.00
- Revenue This Year
- NAUT N/A
- SPRO N/A
- Revenue Next Year
- NAUT N/A
- SPRO N/A
- P/E Ratio
- NAUT N/A
- SPRO N/A
- Revenue Growth
- NAUT N/A
- SPRO N/A
- 52 Week Low
- NAUT $0.62
- SPRO $0.51
- 52 Week High
- NAUT $3.03
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- NAUT 60.66
- SPRO 59.67
- Support Level
- NAUT $0.69
- SPRO $1.84
- Resistance Level
- NAUT $0.92
- SPRO $2.05
- Average True Range (ATR)
- NAUT 0.06
- SPRO 0.08
- MACD
- NAUT 0.01
- SPRO 0.03
- Stochastic Oscillator
- NAUT 70.67
- SPRO 83.86
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.